Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: A systematic review and meta-analysis of prognostic factors
Số trang: 17
Loại file: pdf
Dung lượng: 1.57 MB
Lượt xem: 8
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Combination chemoimmunotherapy (CIT) consisting of anti-CD20 has improved the progression-free survival (PFS) and overall survival (OS) of patients with chronic lymphocytic leukaemia (CLL). We performed a comprehensive synthesis of prognostic factors in patients with CLL on combined CIT with anti-CD20 antibodies compared with standard chemotherapy alone or targeted therapy.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Chronic lymphocytic leukaemia Anti-CD20 Targeted therapy Combination chemoimmunotherapy Overall survivalGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 166 0 0 -
6 trang 165 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 138 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 106 0 0 -
12 trang 86 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 34 0 0
-
12 trang 33 0 0